List of Contributors |
|
xi | |
Part I General Aspects: Skeletal Muscle Physiology And Nutrition |
|
|
1 Skeletal Muscle Mass Indices in Healthy Adults |
|
|
|
|
Roxana E. Ruiz Valenzuela |
|
|
|
3 | (1) |
|
The Biological Bases That Underlie the Indices |
|
|
4 | (2) |
|
Different Skeletal Muscle Indices Generated Worldwide |
|
|
6 | (4) |
|
Clinical Implications of the Indiscriminate Use of Different Published Indices |
|
|
10 | (2) |
|
|
12 | (1) |
|
|
12 | (6) |
|
2 Reduced Skeletal Muscle Mass and Lifestyle |
|
|
|
|
|
18 | (1) |
|
|
19 | (3) |
|
Combining Physical Activity and Nutrition |
|
|
22 | (3) |
|
Smoking, Alcohol Use and Socioeconomic Status |
|
|
25 | (1) |
|
|
26 | (2) |
|
|
28 | (8) |
|
3 Molecular Mechanisms of Postmeal Regulation of Muscle Anabolism |
|
|
|
|
Cellular Processes Under mTORC1 |
|
|
36 | (2) |
|
|
38 | (2) |
|
|
40 | (1) |
|
|
40 | (8) |
|
4 Adaptation of Skeletal Muscle Mass and Metabolism to Physical Exercise |
|
|
|
|
The Muscular Adaptation to Endurance Training |
|
|
48 | (5) |
|
The Muscular Adaptation to Resistance Training (RT) |
|
|
53 | (4) |
|
The Specific Responses to Concurrent Training |
|
|
57 | (2) |
|
|
59 | (8) |
Part II Pathophysiology Of Skeletal Muscle: The Important Role Of Diet And Nutrients |
|
|
Section 1: Ageing and Sarcopenia |
|
|
|
5 The Role of Specific Nutriments in Sarcopenia Associated With Chronic Diseases: A Focus on Cancer |
|
|
|
|
Sarcopenia in Chronic Diseases |
|
|
67 | (1) |
|
Impact of Sarcopenia on Disease Outcomes in the Chronic Setting |
|
|
68 | (2) |
|
Muscle Anabolism in Cancer Patients |
|
|
70 | (1) |
|
The Role of Total and Specific Amino Acids in Promoting Muscle Anabolism in Cancer |
|
|
71 | (5) |
|
Role of Total and Specific Amino Acids in Promoting Muscle Anabolism in Chronic Disease Other Than Cancer |
|
|
76 | (1) |
|
Role of Omega-3 Fatty Acid Supplementation in Promoting Muscle Anabolism in Cancer Patients |
|
|
77 | (1) |
|
|
78 | (1) |
|
|
78 | (4) |
|
|
82 | (1) |
|
|
|
|
|
|
|
83 | (1) |
|
Sarcopenic Obesity (SO) Definition |
|
|
83 | (2) |
|
|
85 | (1) |
|
Clinical implications of SO |
|
|
86 | (1) |
|
Clinical implications of DAO |
|
|
87 | (1) |
|
|
88 | (1) |
|
|
89 | (1) |
|
|
90 | (2) |
|
|
92 | (1) |
|
7 Effects of Sarcopenic Obesity on Cardiovascular Disease and All-Cause Mortality |
|
|
|
|
|
93 | (1) |
|
Defining Sarcopenic Obesity |
|
|
94 | (1) |
|
Sarcopenic Obesity and Cardiovascular Risk Factors in Older Age |
|
|
95 | (1) |
|
Sarcopenic Obesity and Cardiovascular Disease in Older Age |
|
|
96 | (1) |
|
Sarcopenic Obesity and All-Cause Mortality in Older Age |
|
|
96 | (5) |
|
|
101 | (1) |
|
|
101 | (7) |
|
Section 2: Obesity, High Fat, and Overfeeding |
|
|
|
8 Skeletal Muscle in Obesity and Chronic Overfeeding |
|
|
|
|
|
108 | (1) |
|
|
109 | (1) |
|
Skeletal Muscle Protein Metabolism and Obesity |
|
|
109 | (2) |
|
|
111 | (1) |
|
|
112 | (1) |
|
|
112 | (5) |
|
9 Skeletal Muscle Mitochondrial, Obesity, and High-Fat Feeding |
|
|
|
|
|
117 | (1) |
|
|
118 | (1) |
|
Muscle Oxidative Capacities |
|
|
118 | (2) |
|
Factors Involved in Mitochondria Dysfunction |
|
|
120 | (1) |
|
|
121 | (1) |
|
|
121 | (4) |
|
10 Muscle Immune Cells, Obesity, and High-Fat Feeding |
|
|
|
|
|
|
|
125 | (1) |
|
Obesity, High-Fat Feeding, Muscle Immune Cell Infiltration, and Activation |
|
|
125 | (3) |
|
Obesity, High-Fat Feeding, and Muscle Regeneration Capacity |
|
|
128 | (4) |
|
|
132 | (1) |
|
|
132 | (7) |
|
Section 3: Physical Exercise |
|
|
|
11 Physiological Regulation of Skeletal Muscle Mass: Resistance Exercise-Mediated Muscle Hypertrophy |
|
|
|
|
|
|
139 | (1) |
|
Resistance Exercise and Protein Synthesis |
|
|
140 | (3) |
|
Resistance Exercise and Ribosomal Biogenesis |
|
|
143 | (2) |
|
Resistance Exercise and Satellite Cells |
|
|
145 | (1) |
|
|
146 | (1) |
|
|
147 | (1) |
|
|
147 | (1) |
|
|
147 | (4) |
|
12 Training, Changes in Nutritional Requirements and Dietary Support of Physical Exercise |
|
|
|
|
Introduction Into the Role of Nutrition on Adaptive Effects of Exercise |
|
|
151 | (1) |
|
Acute and Chronic Exercise: Stress and Adaptation |
|
|
152 | (5) |
|
|
157 | (8) |
|
Does Exercise-Related Requirement Justify Micronutrient Supplement Use? |
|
|
165 | (7) |
|
Health Claims and the "Beneficial" Expected Effects |
|
|
172 | (2) |
|
|
174 | (3) |
|
Conclusion and Key Messages |
|
|
177 | (1) |
|
|
177 | (6) |
|
13 Proteins and Amino Acids and Physical Exercise |
|
|
|
|
|
|
|
183 | (1) |
|
Sources of Protein Intake |
|
|
184 | (1) |
|
|
184 | (1) |
|
Endurance Exercise Performance |
|
|
184 | (3) |
|
Resistance Exercise Performance |
|
|
187 | (2) |
|
|
189 | (3) |
|
|
192 | (5) |
|
14 Physical Exercise in Chronic Diseases |
|
|
|
|
|
197 | (1) |
|
|
197 | (1) |
|
|
198 | (12) |
|
Cardiovascular and Pulmonary Diseases |
|
|
210 | (19) |
|
|
229 | (1) |
|
|
229 | (1) |
|
|
229 | (22) |
Part III Nutrition As A Therapeutical Tool For Skeletal Muscle |
|
|
Section 4: Amino Acid Supplements |
|
|
|
15 Whey Protein and Muscle Protection |
|
|
|
|
Skeletal Muscle Loss and Protein Nutrition |
|
|
251 | (2) |
|
Interest of "Fast" Proteins for Muscle Anabolic Response |
|
|
253 | (3) |
|
|
256 | (1) |
|
|
256 | (7) |
|
16 Branched-Chain Amino Acids (Leucine, Isoleucine, and Valine) and Skeletal Muscle |
|
|
|
|
|
|
263 | (1) |
|
|
263 | (2) |
|
BCAA Requirement and Tolerable Upper Intake Level |
|
|
265 | (1) |
|
|
266 | (1) |
|
mTOR Signaling and Muscle Protein Synthesis |
|
|
267 | (3) |
|
Acute Effects of BCAA Intake on Muscle Protein Synthesis |
|
|
270 | (1) |
|
The Leucine Content of Dietary Protein: A Determinant of the Anabolic Potential? |
|
|
271 | (1) |
|
Chronic Effects of BCAA Supplementation and Muscle Growth |
|
|
272 | (2) |
|
BCAAs and Insulin Resistance |
|
|
274 | (1) |
|
|
275 | (1) |
|
|
275 | (1) |
|
|
275 | (1) |
|
|
276 | (3) |
|
17 Glutamine and Skeletal Muscle |
|
|
|
|
An Introduction to Glutamine Metabolic Biochemistry |
|
|
279 | (1) |
|
Glutamine Metabolic Biochemistry in Skeletal Muscles |
|
|
280 | (4) |
|
Glutamine Nutritional Properties in Skeletal Muscles |
|
|
284 | (4) |
|
Important Considerations of Glutamine Supplementation |
|
|
288 | (2) |
|
|
290 | (1) |
|
|
290 | (5) |
|
18 Arginine and Skeletal Muscle |
|
|
|
|
|
295 | (1) |
|
|
296 | (2) |
|
Arginine and Muscle Creatine |
|
|
298 | (1) |
|
Arginine and Endothelial Function |
|
|
299 | (1) |
|
Arginine and Muscle Protein Homeostasis |
|
|
299 | (3) |
|
Arginine and Muscle Function |
|
|
302 | (1) |
|
Arginine and Tissue Healing |
|
|
303 | (1) |
|
Arginine and Muscle Protein Homeostasis in Acute Injury |
|
|
304 | (1) |
|
|
305 | (1) |
|
|
305 | (7) |
|
19 Citrulline and Skeletal Muscle |
|
|
|
|
|
|
|
312 | (1) |
|
|
313 | (2) |
|
20 Sulfur Amino Acids and Skeletal Muscle |
|
|
|
|
|
|
|
|
|
|
General Biochemical Aspects on Sulfur Amino Acids |
|
|
315 | (9) |
|
Sulfur Amino Acids and Related Compounds in Skeletal Muscle |
|
|
324 | (8) |
|
Sulfur Amino Acids Requirements and Supplementations |
|
|
332 | (4) |
|
|
336 | (11) |
|
Section 5: Dietary Lipids |
|
|
|
21 Regulation of Skeletal Muscle Metabolism by Saturated and Monounsaturated Fatty Acids |
|
|
|
|
|
|
347 | (2) |
|
Mechanisms of Action of SFA and MUFA in Skeletal Muscle |
|
|
349 | (5) |
|
Lifestyle Interventions to Alleviate SFA-Mediated Lipotoxicity in Skeletal Muscle |
|
|
354 | (1) |
|
|
354 | (1) |
|
|
355 | (4) |
|
22 Polyunsaturated Omega-3 Fatty Acids and Skeletal Muscle |
|
|
|
|
|
359 | (1) |
|
|
359 | (1) |
|
What Are Polyunsaturated Omega-3 Fatty Acids? |
|
|
359 | (2) |
|
Regulation of Muscle Mass |
|
|
361 | (1) |
|
Effect of Omega-3 Fatty Acids on Muscle Protein Turnover |
|
|
362 | (2) |
|
|
364 | (2) |
|
Strength and Physical Function |
|
|
366 | (1) |
|
|
367 | (1) |
|
|
367 | (1) |
|
|
367 | (8) |
|
|
|
23 Vitamin D Signaling and Skeletal Muscle Cells |
|
|
|
|
|
|
375 | (1) |
|
Vitamin D and Skeletal Muscle Function |
|
|
376 | (2) |
|
Vitamin D and Skeletal Muscle Morphology |
|
|
378 | (1) |
|
Vitamin D Status and Skeletal Muscle Development and Regeneration |
|
|
379 | (2) |
|
Effect of Vitamin D on Skeletal Muscle Cell Signaling |
|
|
381 | (2) |
|
Genetic Contribution to Vitamin D Effects |
|
|
383 | (1) |
|
The Complex Action of Vitamin D |
|
|
383 | (1) |
|
|
384 | (1) |
|
|
384 | (5) |
|
24 Vitamin D Deficiency and Myopathy |
|
|
|
|
|
389 | (1) |
|
|
389 | (1) |
|
Muscle Weakness and Vitamin D Deficiency |
|
|
390 | (1) |
|
Muscle Pain and Vitamin D Deficiency |
|
|
391 | (1) |
|
Vitamin D and Physical Performance Measures |
|
|
392 | (1) |
|
Falls and Vitamin D Deficiency |
|
|
393 | (1) |
|
|
394 | (1) |
|
|
395 | (6) |
|
Section 7: Nutraceuticals and Phytochemicals |
|
|
|
25 Phytochemicals, Their Intestinal Metabolites, and Skeletal Muscle Function |
|
|
|
|
|
401 | (1) |
|
|
401 | (1) |
|
Cultured Skeletal Muscle Cells and Incubated Muscle Tissues as Useful Bioassay Systems to Search for Novel Bioactive Factors |
|
|
402 | (1) |
|
Glucose Uptake Assay in Cultured L6 Myotubes for Initial Screening of Novel Phytochemicals |
|
|
403 | (2) |
|
Phytochemicals, Glucose Metabolism in Skeletal Muscle Cells and Their Effects on T2D Model Animals |
|
|
405 | (8) |
|
Plant Hormones and Muscle Function |
|
|
413 | (1) |
|
Direct Molecular Target of Phytochemicals that Activate AMPK |
|
|
414 | (1) |
|
Bromacology: Pharmacology of Food and Their Components |
|
|
414 | (1) |
|
|
414 | (1) |
|
|
415 | (4) |
|
26 Antioxidants and Polyphenols Mediate Mitochondrial Mediated Muscle Death Signaling in Sarcopenia |
|
|
|
|
|
419 | (1) |
|
|
420 | (1) |
|
Mitochondrial Function in Aging Muscles and Motor Neurons |
|
|
421 | (2) |
|
Potential Sources of Mitochondrial Dysfunction in Aging |
|
|
423 | (2) |
|
PGC-LCS Regulation of Mitochondria in Sarcopenia |
|
|
425 | (2) |
|
Mitochondria are Initiators of Cell Death Signaling in Aging Muscles |
|
|
427 | (3) |
|
|
430 | (4) |
|
Linking Autophagy and Apoptosis |
|
|
434 | (1) |
|
Ubiquitin Proteasome System |
|
|
435 | (2) |
|
Mitochondria, Mitophagy, and the Ubiquitin Proteasome System (UPS) |
|
|
437 | (1) |
|
Localized Apoptotic Signaling Spreads to Remove the Entire Fiber in Sarcopenia |
|
|
438 | (2) |
|
Potential for Nutritional Strategies to Reverse Mitochondrial Death Signaling |
|
|
440 | (19) |
|
|
459 | (2) |
|
|
461 | (14) |
|
27 β-Conglycinin and Skeletal Muscle |
|
|
|
|
|
|
475 | (1) |
|
|
475 | (1) |
|
Effects of β-Conglycinin on Lowering of Blood Triglycerides |
|
|
476 | (1) |
|
Promotion of Adiponectin Production |
|
|
476 | (1) |
|
β-Conglycinin Influence Glucose Metabolism in Skeletal Muscle |
|
|
477 | (1) |
|
Peptides Derived from β-Conglycinin Modulate GLUT4 Translocation |
|
|
478 | (1) |
|
A Novel Protein Similar to β-Conglycinin: Mung Bean Protein |
|
|
478 | (1) |
|
|
479 | (3) |
|
|
482 | (3) |
|
28 Effects of Quercetin on Mitochondriogenesis in Skeletal Muscle: Consequences for Physical Endurance and Glycemic Control |
|
|
|
Alfredo Fernandez-Quintela |
|
|
|
|
|
|
|
|
485 | (1) |
|
|
486 | (2) |
|
Quercetin and Physical Endurance |
|
|
488 | (3) |
|
Quercetin and Glucose Tolerance |
|
|
491 | (4) |
|
|
495 | (1) |
|
|
495 | (1) |
|
|
495 | |
Part IV Adverse Effects Due To Drugs And Alcohol |
|
|
29 Statins and Muscle Damage |
|
|
|
|
|
499 | (1) |
|
Definition of Muscle Toxicity |
|
|
499 | (1) |
|
|
500 | (2) |
|
|
502 | (1) |
|
|
502 | (1) |
|
|
502 | (1) |
|
Autoimmune-Mediated Necrotizing Myositis |
|
|
503 | (1) |
|
Risk Factors for Muscle Toxicity |
|
|
504 | (1) |
|
Mechanism of Muscle Toxicity |
|
|
504 | (1) |
|
|
505 | (1) |
|
|
506 | (1) |
|
|
506 | (3) |
|
|
|
|
|
|
Candelaria Martin-Gonzalez |
|
|
|
Francisco Santolaria-Fernandez |
|
|
|
509 | (1) |
|
|
510 | (1) |
|
|
511 | (3) |
|
|
514 | (6) |
|
Future Prospects. Effects on Distant Organs |
|
|
520 | (2) |
|
|
522 | (1) |
|
|
522 | (7) |
Index |
|
529 | |